US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.
Zongertinib: A Potential Treatment for HER2 Mutation Positive NSCLC Patients
Zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) developed by BI, is under development specifically to target NSCLC patients with HER2 mutations. This targeted approach to treatment has the potential to significantly improve patient outcomes by addressing the underlying genetic mutations that drive the disease.
Guardant360 CDx: A Comprehensive Liquid Biopsy for Advanced Solid Tumors
Guardant360 CDx is the first FDA-approved comprehensive liquid biopsy designed for all advanced solid tumors. Its approval as a companion diagnostic (CDx) for multiple targeted therapies in NSCLC further solidifies its role in personalized medicine. The collaboration between Guardant Health and Boehringer Ingelheim is expected to leverage the strengths of both companies to advance this innovative diagnostic tool, potentially leading to more effective treatment strategies for patients.-Fineline Info & Tech
